The Role Of PRDM1 and Its Interacting Proteins In The Pathogenesis Of Chronic Lymphocytic Leukemia »
05/02/14

Effective Inhibition Of Tumor Microenvironment Interactions In CLL Patients Treated With The BTK Inhibitor Ibrutinib Results In Sustained Inhibition Of Tumor Proliferation and Survival Pathways »
05/02/14

Synthetic Lethality In CLL With DNA Damage Response Defect By Targeting ATR Pathway »
05/02/14

CMV-Specific CD8+ T-CELL Function Is NOT Impaired In CLL »
05/02/14

SF3B1 Mutations Frequently Occur With Both ATM Mutations and TP53 Mutations In CLL Patients »
05/02/14

R-DHAP Immunochemotherapy Is An Effective Remission-Induction Treatment For CLL Patients With Fludarabine Refractory Disease With Or Without Deletion 17p, Enabling The Majority To Proceed To Allogeneic Stem Cell Transplantation »
05/02/14

A Novel Automated Analysis Of Flow Cytometry Data Identifies Distinct Cell Signatures In The Immune System Of CLL Patients »
05/02/14

Drug Screening Reveals That Ibrutinib (PCI-32765) Exhibits Synergy With BCL-2 and Proteasome Inhibitors In Models Of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) »
05/02/14

Idelalisib, a Selective Inhibitor Of PI3KI´, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) »
05/02/14

Outcome Of Chronic Lymphocytic Leukemia (CLL) Patients That Failed Allogeneic Stem Cell Transplantation »
05/02/14